NCT05362682 is a clinical trial of Sinopharm Vaccine in Sars-CoV-2 Infection, sponsored by International Vaccine Institute.

Who is sponsoring NCT05362682?

NCT05362682 is sponsored by International Vaccine Institute.

What drugs are being tested in NCT05362682?

Interventions in NCT05362682: Sinopharm Vaccine.

What condition does NCT05362682 study?

NCT05362682 studies Sars-CoV-2 Infection.

Is NCT05362682 still recruiting?

NCT05362682 is currently status unknown. Last updated 19 April 2023.

Last reviewed 2023-04-19 · How we verify

NCT05362682

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effectiveness Evaluation of the Sinopharm Vaccine in the Dondo District in Mozambique

Status unknown Last updated 19 April 2023

What this trial tests

trial testing Sinopharm Vaccine in Sars-CoV-2 Infection in 3,000 participants. Status unknown.

Timeline

24 February 2022

Primary endpoint
28 February 2024

30 August 2024

Quick facts

Lead sponsor	International Vaccine Institute
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	3,000
Start date	24 February 2022
Primary completion	28 February 2024
Estimated completion	30 August 2024
Sites	1 location across Mozambique

Drugs / interventions tested

Sinopharm Vaccine — full drug profile →

Conditions studied

Sars-CoV-2 Infection — all drugs for Sars-CoV-2 Infection →

Sponsor

International Vaccine Institute

Who can join

18 and older, any sex, with Sars-CoV-2 Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Three complementary activities will be implemented:1) Baseline and repeat census of the catchment population; described in a separate protocol (IVI-ECOVA-03-WS1); 2) Enhanced surveillance for COVID-19 disease, and 3) AEFI-enhanced surveillance. The mass vaccination campaign will be conducted by the Government and is not part of this protocol.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Sars-CoV-2 Infection

Currently open trials in the same condition.

NCT06631287 — Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Sym · Phase 3 · recruiting
NCT04964115 — Post Acute Sequelae of COVID-19 · active not recruiting

Other International Vaccine Institute trials

Trials by the same sponsor.

NCT07377656 — Strengthening HPV Immunization Through EPI Leveraged Delivery · Phase 2 · not yet recruiting
NCT07093489 — Evaluation of Effectiveness and Safety of LC16m8 Mpox Vaccine in the Democratic Republic of Congo (DRC) · not yet recruiting
NCT06800131 — Hepatitis B Vaccine Delivered Trans-dermally by MAP · Phase 1 · not yet recruiting
NCT05762393 — A Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Sm-p80 + GLA-SE (SchistoShield®) Candidate Vacci · Phase 1 · completed
NCT05559983 — Dose Escalation Study to Evaluate the Safety and Immunogenicity of the Cholera Conjugate Vaccine in Healthy Adults · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05362682 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by International Vaccine Institute
Last refreshed: 19 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05362682.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing